检索结果-南通市图书馆

Association between serumα-L-fucosidase andnon-alcoholic fatty liver disease:Cross-sectional study

在线全文

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2016年第5期22卷 1884-1890页

作者： Zhen-ya Lu Chao Cen zhou shao Xin-hua chen cheng-fu xu you-ming li Department of Internal Medicine the First Affiliated Hospital of Zhejiang University School of MedicineHangzhou 310009Zhejiang ProvinceChina Division of Hepatobiliary and Pancreatic Surgery Department of Surgerythe First Affiliated Hospital of Zhejiang University School of MedicineHangzhou 310009Zhejiang ProvinceChina Department of Gastroenterology the First Affiliated Hospital of Zhejiang University School of MedicineHangzhou 310003Zhejiang ProvinceChina

AIM: To explore the association between serum α-Lfucosidase(Af U) and non-alcoholic fatty liver disease(NAf LD).METHODS: A total of 16473 individuals(9456 men and 7017 women) were included in the current study, who presented for a health examination at the first Affiliated hospital of Zhejiang University School of medicine in 2014. The baseline characteristics of the cohort were compared by NAf LD status. linear regression analysis and stepwise multiple regression analysis were applied to assess the risk factors for NAf LD. Receiver operating characteristic curve was used to determine the sensitivity and specificity of Af U in the diagnosis of NAf ***: The prevalence rates of NAf LD and metabolic syndrome(met S) were 38.0% and 25.4%, respectively. The NAf LD group had significantly higher Af U levels than the non-NAf LD group(28.7 ± 7.9 U/L vs 26.0 ± 7.3 U/L, P lipoprotein cholesterol, and elevated blood pressure and fasting glucose. Stepwise multiple logistic regression analysis showed that Af U was associated with an increased risk of NAf LD(OR = 1.009, 95%CI: 1.003-1.014, P < 0.001). The best cut-off value of Af U for the diagnosis of NAf LD was 27.5 U/L. The area under the curve(diagnostic efficacy index) was 0.606. The sensitivity and specificity were 54.6% and 61.8%, respectively. CONCLUSION: Af U level is significantly associated with NAf LD, and elevated Af U level is an independent risk factor for NAf LD.

关键词： α-L-fucosidase Biomarker non-alcoholicfatty liver disease metabolic syndrome Cross-sectionalstudy

Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Cancer Biology & Medicine 2019年第1期16卷 189-204页

作者： xuchao Zhang Zhiyong liang Shengyue Wang Shun Lu Yong Song Ying cheng Jianming Ying weiping liu Yingyong Hou Yangqiu li Yi liu Jun Hou Xiufeng liu Jianyong shao Yanhong Tai Zheng Wang li fu Hui li Xiaojun zhou hua Bai Mengzhao Wang you Lu Jinji Yang Wenzhao Zhong Qing zhou xuening Yang Jie Wang cheng huang Xiaoqing liu Xiaoyan zhou Shirong Zhang Hongxia Tian Yu chen Ruibao Ren ning liao Chunyan Wu Zhongzheng Zhu Hongming Pan Yanhong Gu liwei Wang Yunpeng liu Suzhan Zhang Tianshu liu Gong chen Zhimin shao Binghe xu Qingyuan Zhang Ruihua xu lin Shen Yilong Wu Guangdong Lung Cancer Institute Medical Research Center Cancer Center of Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences Affiliated Guangdong Provincial People's Hospital South China University of Technology Department of Pathology Peking Union Medical College Hospital Chinese Academy of Medical Sciences National Research Center for Translational Medicine Shanghai Rui Jin Hospital Shanghai Jiao Tong University School of Medicine Lung Tumor Clinical Medical Center Shanghai Chest Hospital Shanghai Jiao Tong University Division of Respiratory Medicine Jinling Hospital Nanjing University School of Medicine Department of Oncology Jilin Cancer Hospital Department of Pathology National Cancer Center/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Department of Pathology West China Hospital Sichuan University Department of Pathology Zhongshan Hospital Fudan University Department of Hematology First Affiliated Hospital Institute of Hematology School of Medicine Jinan University Laboratory of Oncology Affiliated Hospital of the Academy of Military Medical Sciences Department of Oncology First Clinical College of South China University of Technology/Guangdong Lung Cancer Institute People's liberation Army Cancer Center of Bayi Hospital Affiliated to Nanjing University of Chinese Medicine Department of Pathology Sun Yat-sen University Cancer Center Department of Pathology Affiliated Hospital of the Academy of Military Medical Sciences Department of Pathology Beijing Hospital Department of Breast Cancer Pathology and Research Laboratory of Cancer Tianjin Medical University Cancer Institute and Hospital National Clinical Research Center for Cancer Key Laboratory of Cancer Prevention and Therapy Tianjin Tianjin’s Clinical Research Center for Cancer Department of Pathology Jinling Hospital Nanjing University School of Medicine State Key Laboratory of Molecular Oncology Department of Medical Oncology National Cancer Center/Canc

Next-generation sequencing(NGS) technology is capable of sequencing millions or billions of DNA molecules ***, it represents a promising tool for the analysis of molecular targets for the initial diagnosis of disease, monitoring of disease progression, and identifying the mechanism of drug resistance. On behalf of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology(CSCO) and the China Actionable Genome Consortium(CAGC), the present expert group hereby proposes advisory guidelines on clinical applications of NGS technology for the analysis of cancer driver genes for precision cancer therapy. This group comprises an assembly of laboratory cancer geneticists, clinical oncologists, bioinformaticians,pathologists, and other professionals. After multiple rounds of discussions and revisions, the expert group has reached a preliminary consensus on the need of NGS in clinical diagnosis, its regulation, and compliance standards in clinical sample collection. Moreover, it has prepared NGS criteria, the sequencing standard operation procedure(SOP), data analysis, report, and NGS platform certification and validation.

关键词： Next-generation sequencing technology cancer consensus

Efficacy and safety of Shenyankangfu Tablet,a Chinese patent medicine,for primary glomerulonephritis:A multicenter randomized controlled trial

在线全文

学校读者我要写书评

暂无评论

Journal of Integrative Medicine 2021年第2期19卷 111-119页

作者： Jie Wu Shu-wei Duan Hong-tao Yang Yue-yi Deng wei li Ya-ni He Zhao-hui Ni Yong-li Zhan Shan lin Zhi-yong Guo Jun Zhu Jing-ai Fang xu-sheng liu li-hua Wang Rong Wang Nian-song Wang Xiao-hong cheng li-qun He Ping Luo Shi-ren Sun Ji-feng Sun Ai-ping Yin Geng-ru Jiang Hong-yu chen Wen-hu liu Hong-li lin Meng liang Lu Ma ming chen li-qun Song Jian chen Qing Zhu Chang-ying xing Yun li Ji-ning Gao Rong-shan li Ying li Hao Zhang Ying Lu Qiao-ling zhou Jun-zhou fu Qiang He Guang-yan Cai Xiang-mei chen Department of Nephrology Chinese People’s Liberation Army General HospitalChinese People’s Liberation Army Institute of NephrologyState Key Laboratory of Kidney Diseases(2011DAV00088)National Clinical Research Center for Kidney DiseasesBeijing 100853China Department of Nephrology First Teaching Hospital of Tianjin University of Traditional Chinese MedicineTianjin 300192China Department of Nephrology Longhua HospitalShanghai University of Traditional Chinese MedicineShanghai 200032China Department of Nephrology Shandong University of Traditional Chinese Medicine Affiliated HospitalJinan 250011.Shandong ProvinceChina Department of Nephrology Daping HospitalArmy Medical UniversityChongqing 400042China Department of Nephrology Renji HospitalShanghai Jiao Tong UniversityShanghai 200127China Department of Nephrology Guang’anmen HospitalChina Academy of Traditional Chinese Medical SciencesBeijing 100053China Department of Nephrology Tianjin Medical University General HospitalTianjin 300052China Department of Nephrology Changhai Hospital of ShanghaiNaval Medical UniversityShanghai 200433China Department of Nephrology West China HospitalChengdu 610083Sichuan ProvinceChina Department of Nephrology First Affiliated Hospital of Shanxi Medical UniversityTaiyuan 030001Shanxi ProvinceChina Department of Nephrology Guangdong Provincial Hospital of Chinese MedicineGuangzhou 510120Guangdong ProvinceChina Department of Nephrology Shanxi Medical University Second Affiliated HospitalTaiyuan 030001Shanxi ProvinceChina Department of Nephrology Shandong Provincial HospitalJinan 250021Shandong ProvinceChina Department of Nephrology and Rheumatology Affiliated Sixth People’s HospitalShanghai Jiao Tong UniversityShanghai 200233China Department of Nephrology Shaanxi Traditional Chinese Medicine HospitalXi'an 710003Shaanxi ProvinceChina Department of Nephrology Shuguang HospitalShanghai University of Traditional Chinese MedicineShanghai 200021China Department of Nephrology Jilin University Se

Background:Shenyankangfu Tablet(SYKFT)is a Chinese patent medicine that has been used widely to decrease proteinuria and the progression of chronic kidney ***:This trial compared the efficacy and safety of SYKFT,for the control of proteinuria in primary glomerulonephritis patients,against the standard drug,losartan ***,setting,participants and intervention:This was a multicenter,double-blind,randomized,controlled clinical *** glomerulonephritis patients,aged 18-70 years,with blood pressure≤140/90 mmHg,estimated glomerular filtration rate(eGFR)>45 mL/min per 1.73 ㎡,and 24-hour proteinuria level of 0.5-3.0 g,were recruited in 41 hospitals across 19 provinces in China and were randomly divided into five groups:SYKFT,losartan potassium 50 mg or 100 mg,SYKFT plus losartan potassium 50 mg or 100 *** outcome measu res:The primary outcome was change in the 24-hour proteinuria level,after 48 weeks of ***:A total of 735 participants were *** percent decline of urine protein quantification in the SYKFT group after 48 weeks was 8.78%±2.56%(P=0.006)more than that in the losartan 50 mg group,which was 0.51%±2.54%(P=1.000)less than that in the losartan 100 mg *** with the losartan potassium 50 mg group,the SYKFT plus losartan potassium 50 mg group had a 13.39%±2.49%(Pline did not change statistically *** average change in TCM syndrome score between the patients who took SYKFT(-3.00[-6.00,-2.00])and who did not take SYKFT(-2.00[-5.00,0])was statistically significant(P=0.003).No obvious adverse reactions were observed in any ***:SYKFT decreased the proteinur

关键词： Herbal medicine,Chinese Shenyankangfu Tablet Primary glomerulonephritis Randomized controlled trial Double blind Double dummy

The heterogeneity of islet autoantibodies and the progression of islet failure in type 1 diabetic patients

在线全文

学校读者我要写书评

暂无评论

Science China(life Sciences) 2016年第9期59卷 930-939,938-939+932-937页

作者： Jin liu lingling Bian li Ji Yang chen Heng chen Yong Gu Bingqin Ma wei Gu Xinyu xu Yun Shi Jian Wang Dalong Zhu Zilin Sun Jianhua Ma Hui Jin xing Shi Heng Miao Bing Xin Yan Zhu Zhenwen Zhang Ruifang Bu Lan xu Guangde Shi wei Tang wei li Dongmei zhou Jun liang xingbo cheng Bimin Shi Jixiang Dong Ji Hu chen Fang shao Zhong weinan Yu weiping Lu chenguang Wu li Qian Jiancheng Yu Jialin Gao Xiaoqiang Fei Qingqing Zhang xueqin Wang Shiwei Cui Jinluo cheng ning xu Guofeng Wang Guoqing Han Chunrong xu Yun Xie Minmin An wei Zhang Zhixiao Wang Yun Cai Qi fu Yu fu Shuai Zheng Fan Yang Qingfang Hu Hao Dai Yu Jin Zheng Zhang Kuanfeng xu Yifan li Jie Shen Hongwen zhou wei He xuqin Zheng Xiao Han liping Yu Jinxiong She Mei Zhang Tao Yang Department of Endocrinology and Metabolism First Affiliated Hospital of Nanjing Medical University Nanjing 210029 China Barbara Davis Center for Childhood Diabetes University of Colorado Denver Aurora Colorado 80045 USA Key Laboratory of Human functional Genomics of Jiangsu Province Nanjing Medical University Nanjing 210000 China Department of Isotopic Laboratory of Nanjing Medical University Nanjing 210000 China HLA Laboratory of Jiangsu Province People's Hospital Nanjing 210029 China Department of Endocrinology and Metabolism Nanjing General Hospital of Nanjing Military Command Nanjing 210002 China Department of Endocrinology and Metabolism Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School Nanjing 210008 China Department of Endocrinology and Metabolism Zhongda Hospital Southeast University Nanjing 210009 China Department of Endocrinology and Metabolism Nanjing First Hospital Nanjing 210000 China Department of Endocrinology and Metabolism Nanjing Children's Hospital Nanfing 210008 China Department of Endocrinology and Metabolism The Second Affiliated Hospital of Nanjing Medical University Nanjing 210011 China Department of Endocrinology and Metabolism Nanjing Governmental Hospital Nanjing 210008 China Department of Endocrinology and Metabolism Northern Jiangsu People's Hospital Yangzhou 225001 China Department of Endocrinology and Metabolism Wuxi People's Hospital Wuxi 214023 China Department of Endocrinology and Metabolism Jiangsu Jiangyin People's Hospital Wuxi 214400 China Department of Endocrinology and Metabolism The Affiliated Hospital of Xuzhou Medical College Xuzhou 221006 China Department of Endocrinology and Metabolism Xuzhou Central Hospital Xuzhou 221009 China Department of Endocrinology and Metabolism The First Affiliated Hospital of Soochow University Suzhou 215006 China Department of Endocrinology and Metabolism The Second Affiliated Hospital of Soochow University Suzhou 215004 China Department of Endocri

Type 1 diabetes mellitus is heterogeneous in many facets. The patients suffered from type 1 diabetes present several levels of islet function as well as variable number and type of islet-specific autoantibodies. This study was to investigate prevalence and heterogeneity of the islet autoantibodies and clinical phenotypes of type 1 diabetes mellitus; and also discussed the process of islet failure and its risk factors in Chinese type 1 diabetic patients. A total of 1,291 type 1 diabetic patients were enrolled in this study. Demographic information was collected. Laboratory tests including mixed-meal tolerance test, human leukocyte antigen alleles, hemoglobin A1 c, lipids, thyroid function and islet autoantibodies were conducted. The frequency of islet-specific autoantibody in newly diagnosed T1 DM patients(duration shorter than half year) was 73% in East China. According to binary logistic regressions, autoantibody positivity, longer duration and lower Body Mass Index were the risk factors of islet failure. As the disease developed, autoantibodies against glutamic acid decarboxylase declined as well as the other two autoantibodies against zinc transporter 8 and islet antigen 2. The decrease of autoantibodies was positively correlated with aggressive beta cell destruction. Autoantibodies can facilitate the identification of classic T1 DM from other subtypes and predict the progression of islet failure. As there were obvious heterogeneity in autoantibodies and clinical manifestation in different phenotypes of the disease, we should take more factors into consideration when identifying type 1 diabetes mellitus.

关键词： autoantibodies heterogeneity islet failure type 1 diabetes

The first data release(DR1) of the LAMOST regular survey

在线全文

学校读者我要写书评

暂无评论

Research in Astronomy and Astrophysics 2015年第8期15卷 1095-1124页

作者： A-li Luo Yong-Heng Zhao Gang Zhao li-Cai Deng Xiao-wei liu Yi-Peng Jing Gang Wang Hao-Tong Zhang Jian-Rong Shi Xiang-Qun Cui Yao-Quan Chu Guo-Ping li Zhong-Rui Bai Yue Wu Yan Cai Shu-Yun Cao Zi-huang Cao Jeffrey L.Carlin Hai-Yuan chen Jian-Jun chen Kun-Xin chen li chen xue-Lei chen Xiao-Yan chen Ying chen Norbert Christlieb Jia-Ru Chu chen-zhou Cui Yi-Qiao Dong Bing Du Dong-wei Fan Lei Feng Jian-ning fu Peng Gao xue-Fei Gong Bo-Zhong Gu Yan-Xin Guo Zhan-Wen Han Bo-liang He Jin-liang Hou Yong-Hui Hou Wen Hou Hong-Zhuan Hu ning-Sheng Hu Zhong-Wen Hu Zhi-Ying Huo Lei Jia Fang-hua Jiang Xiang Jiang Zhi-Bo Jiang Ge Jin Xiao Kong xu Kong Ya-Juan Lei Ai-hua li Chang-hua li Guang-wei li Hai-ning li Jian li Qi li Shuang li Sha-Sha li Xin-Nan li Yan li Yin-Bi li Ye-Ping li Yuan liang Chien-cheng lin Chao liu Gen-Rong liu Guan-Qun liu Zhi-Gang liu Wen-Zhi Lu Yu Luo Yin-Dun Mao Heidi Newberg Ji-Jun Ni Zhao-Xiang Qi Yong-Jun Qi Shi-Yin Shen Huo-ming Shi Jing Song Yi-Han Song Ding-Qiang Su Hong-Jun Su Zheng-Hong Tang Qing-Sheng Tao Yuan Tian Dan Wang Da-Qi Wang Feng-Fei Wang Guo-Min Wang Hai Wang Hong-Chi Wang Jian Wang Jia-ning Wang Jian-ling Wang Jian-Ping Wang Jun-Xian Wang Lei Wang Meng-Xin Wang Shou-Guan Wang Shu-Qing Wang Xia Wang Ya-Nan Wang you Wang Yue-Fei Wang you-Fen Wang Peng wei ming-Zhi wei Hong Wu Ke-Fei Wu xue-Bing Wu Yu-Zhong Wu Xiao-Zheng xing ling-Zhe xu Xin-Qi xu Yan xu Tai-Sheng Yan De-hua Yang Hai-Feng Yang Hui-Qin Yang ming Yang Zheng-Qiu Yao Yong Yu Hui Yuan Hai-Bo Yuan Hai-Long Yuan wei-Min Yuan Chao Zhai En-Peng Zhang hua-wei Zhang Jian-Nan Zhang li-Pin Zhang wei Zhang Yong Zhang Yan-Xia Zhang Zheng-Chao Zhang ming Zhao Fang zhou xu zhou Jie Zhu Yong-Tian Zhu Si-cheng Zou Fang Zuo National Astronomical Observatories Chinese Academy of Sciences Department of Astronomy Peking University Shanghai Astronomical Observatory Chinese Academy of Sciences Nanjing Institute of Astronomical Optics & Technology National Astronomical ObservatoriesChinese Academy of Sciences University of Science and Technology of China Department of Physics Applied Physics and AstronomyRensselaer Polytechnic InstituteTroyNY 12180USA Department of Physics and Astronomy Earlham CollegeRichmondIN 47374USA Universitt Heidelberg Zentrum für AstronomieLandessternwarteKnigstuhl 1269117 HeidelbergGermany Department of Astronomy Beijing Normal University Yunnan Observatories Chinese Academy of Sciences Purple Mountain Observatory Chinese Academy of Sciences

The Large sky Area Multi-Object Fiber Spectroscopic Telescope（LAMOST） general survey is a spectroscopic survey that will eventually cover approximately half of the celestial sphere and collect 10 million spectra of stars, galaxies and QSOs. Objects in both the pilot survey and the first year regular survey are included in the LAMOST DR1. The pilot survey started in October 2011 and ended in June 2012, and the data have been released to the public as the LAMOST Pilot Data Release in August 2012. The regular survey started in September 2012, and completed its first year of operation in June 2013. The LAMOST DR1 includes a total of 1202 plates containing 2 955 336 spectra, of which 1 790 879 spectra have observed signalto-noise ratio（SNR） ≥ 10. All data with SNR ≥ 2 are formally released as LAMOST DR1 under the LAMOST data policy. This data release contains a total of 2 204 696 spectra, of which 1 944 329 are stellar spectra, 12 082 are galaxy spectra and 5017 are quasars. The DR1 not only includes spectra, but also three stellar catalogs with measured parameters： late A,FGK-type stars with high quality spectra（1 061 918 entries）, A-type stars（100 073 entries）, and M-type stars（121 522 entries）. This paper introduces the survey design, the observational and instrumental limitations, data reduction and analysis, and some caveats. A description of the FITS structure of spectral files and parameter catalogs is also provided.

关键词： techniques: spectroscopic survey—data release—catalog

Efficacy and safety of sirolimus early conversion protocol in liver transplant patients with hepatocellular carcinoma:A single-arm, multicenter, prospective study

在线全文

学校读者我要写书评

暂无评论

Hepatobiliary & Pancreatic Diseases International 2022年第2期21卷 106-112页

作者： Ren-Yi Su Sun-Bin ling Qiao-Nan Shan xu-Yong wei Rui Wang Chang-Ku Jia li Zhuang Tian Shen li-Min Ding Zhi-Dan xu Lai-Bang Luo li-Bo Sun Guang-ming li Tai-Shi Fang Nan Jiang Kun Zhang Zhao-Jie Su Zhi-Hai Peng Ren Lang Tao Jiang Qiang He lin-Sen Ye Yang Yang Yu-Ting He Wen-Zhi Guo liu-Gen Lan xu-Yong Sun Dong chen Zhi-Shui chen Da-wei zhou shao-Jun Ye Qi-Fa Ye Min Tian Jian-hua Shi Bo Wang Jiang liu Qian Lu wei Rao Jin-Zhen Cai Tao Lv Jia-Yin Yang Pu-Sen Wang lin Zhong Jing-Sheng Ma Qi-Gen li Sheng-Dong Wu Chang-Jiang Lu Cai-De Lu Dong-hua Zhang xuan Wang Zi-Qiang li Mu-Jian Teng Jun-Jie li Wen-Tao Jiang Jian-hua li Quan-Bao Zhang ning-Qi Zhu Zheng-Xin Wang Kang He Qiang Xia shao-hua Song Zhi-Ren fu wei Qiu Guo-Yue Lv Rui-Peng Song Ji-zhou Wang Zheng Wang Jian zhou Gang chen Ying-Peng Zhao li li Ze-Min Hu Qi-Jie Luo Zhong-zhou Si Bin Xie Xiao-Shun He Zhi-Yong Guo Shu-Sen Zheng Xiao xu Department of Hepatobiliary and Pancreatic Surgery The Center for Integrated Oncology and Precision MedicineAffiliated Hangzhou First People’s HospitalZhejiang University School of MedicineHangzhou 310006China NHC Key Laboratory of Combined Multi-organ Transplantation Hangzhou 310003China Department of Hepatobiliary and Pancreatic Surgery Shulan(Hangzhou)HospitalZhejiang Shuren University School of MedicineHangzhou 310022China Department of Hepatobiliary and Pancreatic Surgery The First Affiliated HospitalZhejiang University School of MedicineHangzhou 310003China Department of Transplantation Jiangxi Provincial People’s Hospital Affiliated to Nanchang UniversityNanchang 330006China liver Transplantation Center Beijing You’an HospitalCapital Medical UniversityBeijing 100069China Department of Hepatic Surgery National Clinical Research Center for Infectious DiseaseShenzhen Third People’s HospitalThe Second Affiliated Hospital of Southern University of Science and TechnologyShenzhen 518112China Department of General Surgery Xiang’an Hospital of Xiamen UniversityXiamen 361000China Deartment of Hepatobiliary and Pancreaticosplenic Surgery Beijing Chaoyang HospitalCapital Medical UniversityBeijing 100020China Department of Hepatic Surgery and liver Transplantation Center The Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou 510630China Department of Hepatobiliary and Pancreatic Surgery The First Affiliated Hospital of Zhengzhou UniversityZhengzhou 450052China Department of liver Transplantation The Second Affiliated Hospital of Guangxi Medical UniversityNanning 530000China Institute of Organ Transplantation Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430030China Institute of Hepatobiliary Diseases of Wuhan University Transplant Center of Wuhan UniversityHubei Key Laboratory of Medical Technology on TransplantationZhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Hepatobiliary Surgery The First Affiliated Hos

Mammalian target of rapamycin(m TOR) inhibitor as an attractive drug target with promising antitumor effects has been widely investigated. High quality clinical trial has been conducted in liver transplant(LT) recipients in Western countries. However, the pertinent studies in Eastern world are paucity. Therefore, we designed a clinical trial to test whether sirolimus can improve recurrence-free survival(RFS) in hepatocellular carcinoma(HCC) patients beyond the Milan criteria after LT. This is an open-labeled, single-arm, prospective, multicenter, and real-world study aiming to evaluate the clinical outcomes of early switch to sirolimus-based regimens in HCC patients after LT. Patients with a histologically proven HCC and beyond the Milan criteria will be enrolled. The initial immunosuppressant regimens are center-specifc for the frst 4-6 weeks. The following regimens integrated sirolimus into the regimens as a combination therapy with reduced calcineurin inhibitors based on the condition of patients and centers. The study is planned for 4 years in total with a 2-year enrollment period and a 2-year follow-up. We predict that sirolimus conversion regimen will provide survival benefts for patients particular in the key indicator RFS as well as better quality of life. If the trial is conducted successfully, we will have a continued monitoring over a longer follow-up time to estimate indicator of overall survival. We hope that the outcome will provide better evidence for clinical decision-making and revising treatment guidelines based on Chinese population data.

关键词： Sirolimus Immunosuppressive agents Hepatocellular carcinoma liver transplantation Conversion

Timing analysis of the black hole candidate EXO 1846–031 with Insight-HXMT monitoring

在线全文

学校读者我要写书评

暂无评论

Research in Astronomy and Astrophysics 2021年第3期21卷 193-204页

作者： He-Xin liu Yue huang Guang-cheng Xiao Qing-Cui Bu Jin-Lu Qu Shu Zhang Shuang-Nan Zhang Shu-Mei Jia Fang-Jun Lu Xiang Ma lian Tao wei Zhang li chen li-ming Song Ti-Pei li Yu-Peng xu xue-Lei Cao Yong chen Cong-Zhan liu Ce Cai Zhi Chang Gang chen Tian-Xiang chen Yi-Bao chen Yu-Peng chen wei Cui wei-wei Cui Jing-Kang Deng Yong-wei Dong Yuan-Yuan Du Min-xue fu Guan-hua Gao He Gao Min Gao ming-Yu Ge Yu-Dong Gu Ju Guan cheng-cheng Guo Da-wei Han Jia Huo Lu-hua Jiang wei-Chun Jiang Jing Jin Yong-Jie Jin ling-Da Kong Bing li cheng-Kui li Gang li Mao-Shun li wei li Xian li Xiao-Bo li xu-Fang li Yang-Guo li Zheng-wei li Xiao-hua liang Jing-Yuan liao Bai-Sheng liu Guo-Qing liu Hong-wei liu Xiao-Jing liu Yi-Nong liu Bo Lu xue-Feng Lu Qi Luo Tao Luo Bin Meng Yi Nang Jian-Yin Nie Ge Ou Na Sai Ren-cheng Shang Xin-Ying Song liang Sun Ying Tan you-li Tuo chen Wang Guo-Feng Wang Juan Wang ling-Jun Wang Weng-Shuai Wang Yu-Sa Wang Xiang-Yang Wen Bai-Yang Wu Bo-Bing Wu Mei Wu Shuo Xiao shao-lin Xiong He xu Jia-wei Yang Sheng Yang Yan-Ji Yang Yi-Jung Yang Qi-Bin Yi Qian-Qing Yin Yuan you Ai-Mei Zhang cheng-Mo Zhang Fan Zhang Hong-Mei Zhang Juan Zhang Tong Zhang Wan-Chang Zhang Wen-Zhao Zhang Yi Zhang Yi-Fei Zhang Yong-Jie Zhang Yuan-Hang Zhang Yue Zhang Zhao Zhang Zhi Zhang Zi-liang Zhang Hai-Sheng Zhao Xiao-Fan Zhao Shi-Jie Zheng Yao-Guang Zheng Deng-Ke zhou Jian-Feng zhou Yu-xuan Zhu Ren-lin Zhuang Yue Zhu Key Laboratory of Particle Astrophysics Institute of High Energy PhysicsChinese Academy of SciencesBeijing 100049China University of Chinese Academy of Sciences Chinese Academy of SciencesBeijing 100049China Institut fur Astronomie und Astrophysik Kepler Center for Astro and Particle PhysicsEberhard Karls Universität72076 TubingenGermany Department of Astronomy Beijing Normal UniversityBeijing 100088China Department of Astronomy Tsinghua UniversityBeijing 100084China Department of Physics Tsinghua UniversityBeijing 100084China Department of Engineering Physics Tsinghua UniversityBeijing 100084China Key Laboratory of Space Astronomy and Technology National Astronomical ObservatoriesChinese Academy of SciencesBeijing 100101China College of Physics Sciences&Technology Hebei UniversityBaoding 071002Hebei ProvinceChina

We present the observational results from a detailed timing analysis of the black hole candidate EXO 1846-031 during its outburst in 2019 with the observations of Insight-HXMT,NICER and *** outburst can be classified roughly into four different ***-C quasi-periodic oscillations(QPOs)observed by NICER(about 0.1-6 Hz)and Insight-HXMT(about 0.7-8 Hz)are also reported in this ***,we study various physical quantities related to QPO *** QPO rms-frequency relationship in the energy band 1-10 keV indicates that there is a turning pointing in frequency around2 Hz,which is similar to that of GRS 1915+105.A possible hypothesis for the relationship above may be related to the inclination of the source,which may require a high inclination to explain *** relationships between QPO frequency and QPO rms,hardness,total fractional rms and count rate have also been found in other transient sources,which can indicate that the origin of type-C QPOs is non-thermal.

关键词： X-ray binaries black hole candidate QPO EXO 1846–031

Chemoprophylaxis, diagnosis, treatments, and discharge management of COVID-19: An evidence-based clinical practice guideline(updated version)

在线全文

学校读者我要写书评

暂无评论

Military Medical Research 2020年第3期7卷 249-282页

作者： Ying-Hui Jin Qing-Yuan Zhan Zhi-Yong Peng xue-Qun Ren xun-Tao Yin lin Cai Yu-Feng Yuan Ji-Rong Yue Xiao-Chun Zhang Qi-Wen Yang Jianguang Ji Jian Xia Yi-Rong li fu-Xiang zhou Ya-Dong Gao Zhui Yu Feng xu ming-li Tu li-ming Tan Min Yang Fang chen Xiao-Ju Zhang Mei Zeng Yu Zhu Xin-Can liu Jian Yang Dong-Chi Zhao Yu-Feng Ding ning Hou fu-Bing Wang Hao chen Yong-Gang Zhang wei li Wen chen Yue-Xian Shi Xiu-Zhi Yang xue-Jun Wang Yan-Jun Zhong ming-Juan Zhao Bing-Hui li lin-Lu Ma Hao Zi Na Wang Yun-Yun Wang shao-fu Yu Lu-Yao li Qiao huang Hong Weng Xiang-Ying Ren li-Sha Luo Man-Ru Fan Di huang Hong-Yang xue lin-Xin Yu Jin-Ping Gao Tong Deng Xian-Tao Zeng Hong-Jun li Zhen-Shun cheng Xiao-Mei Yao xing-huan Wang Center for Evidence-Based and Translational Medicine Zhongnan Hospital of Wuhan UniversityWuhan 430071China National Clinical Research Center for Respiratory Diseases China-Japan Friendship HospitalBeijing 100029China Department of Pulmonary and Critical Care Medicine China-Japan Friendship HospitalBeijing 10029China Leishenshan Hospital in Wuhan Wuhan 430200China Department of Critical Care Medicine Zhongnan Hospital of Wuhan UniversityWuhan 430071China Institutes of Evidence-based Medicine and Knowledge Translation Henan UniversityKaifeng 475000HenanChina Department of Medical Imaging Guizhou Provincial People’s HospitalGuiyang 550002China Departments of Orthopedics Zhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Hepatobiliary Surgery Zhongnan Hospital of Wuhan UniversityWuhan 430071China National Clinical Research Center for Geriatrics West China Hospital of Sichuan UniversityChengdu 610041China Department of Geriatrics West China Hospital of Sichuan UniversityChengdu 610041China Department of Radiology Zhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Clinical Laboratory Peking Union Medical College Hospital(PUMCH)Peking Union Medical CollegeChinese Academy of Medical Sciences(CAMS)Beijing 100730China Center for Primary Health Care Research Lund University and Region Skåne25002 MalmöSweden Emergency Center Zhongnan Hospital of Wuhan UniversityWuhan 403371China Department of Allergology Zhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Radiation and Medical Oncology Zhongnan Hospital of Wuhan UniversityWuhan 43071China Department of Critical Care Medicine Renmin Hospital of Wuhan UniversityWuhan 430060China Department of Emergency Medicine and Chest Pain Center Qilu Hospital of Shandong UniversityJinan 250002China Department of Respiratory and Critical Care Medicine Suizhou Central HospitalHubei University of MedicineSuizhou 441300HubeiChina Department of Clinic Pharmacy Second People’s Hospital of Huaihua Ci

The novel severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)is the cause of a rapidly spreading illness,coronavirus disease 2019(COVID-19),affecting more than seventeen million people around the *** and treatment guidelines for clinicians caring for patients are *** the early stage,we have issued"A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus(2019-nCoV)infected pneumonia(standard version)";now there are many direct evidences emerged and may change some of previous recommendations and it is ripe for develop an evidence-based *** formed a working group of clinical experts and *** steering group members proposed 29 questions that are relevant to the management of COVID-19 covering the following areas:chemoprophylaxis,diagnosis,treatments,and discharge *** searched the literature for direct evidence on the management of COVID-19,and assessed its certainty generated recommendations using the Grading of Recommendations,Assessment,Development and Evaluation(GRADE)*** were either strong or weak,or in the form of ungraded consensus-based ***,we issued 34 *** them,6 were strong recommendations for,14 were weak recommendations for,3 were weak recommendations against and 11 were ungraded consensus-based *** covered topics of chemoprophylaxis(including agents and Traditional Chinese Medicine(TCM)agents),diagnosis(including clinical manifestations,reverse transcription-polymerase chain reaction(RT-PCR),respiratory tract specimens,IgM and IgG antibody tests,chest computed tomography,chest X-ray,and CT features of asymptomatic infections),treatments(including lopinavirritonavir,umifenovir,favipiravir,interferon,remdesivir,combination of antiviral drugs,hydroxychloroquine/chloroquine,interleukin-6 inhibitors,interleukin-1 inhibitors,glucocorticoid,qingfei paidu decoction,lianhua qingwen granules/capsules,convalescent plasma,lung

关键词： COVID-19 SARS-CoV-2 Recommendation Chemoprophylaxis Diagnosis Treatment Discharge management Traditional Chinese medicine guideline

Anatomical characteristics of patients with symptomatic severe aortic stenosis in China

在线全文

学校读者我要写书评

暂无评论

Chinese Medical Journal 2021年第22期134卷 2738-2740页

作者： Tian-Yuan Xiong Yi-ming li Yi-Jun Yao Yu-Heng Jia Kai xu Zhen-Fei Fang Jun Jin Guo-Sheng fu Yi-ning Yang Lei Jiang wei-Dong li Yan-Qing Wu Yan-Song Guo Ran Guo Yun-Dai chen Yi li Yi-Bing shao Yi Zhang Bo-Sen Yang Yi-Ke Zhang Jing-Jing He Kai-Yu Jia Sheng-Hu He Fa-Xin Ren Jian-cheng Xiu xing-hua Gu liang-Long chen Ke Han Yuan Feng Mao chen Department of Cardiology West China HospitalSichuan UniversityChengduSichuan 610041China State Key Lab of Hydraulics and Mountain River Engineering Sichuan UniversityChengduSichuan 610044China Department of Cardiology General Hospital of Northern Theater CommandShenyangLiaoning 110015China Department of Cardiology The Second Xiangya Hospital of Central South UniversityChangshaHunan 410011China Department of Cardiology Xinqiao Hospital of Third Military Medical UniversityChongqing 400037China Department of Cardiology Sir Run Run Shaw Hospital of Zhejiang UniversityHangzhouZhejiang 310016China Department of Cardiology The First Affiliated Hospital of Xinjiang Medical UniversityUrumqiXinjiang 830011China Department of Cardiology The Affiliated Hospital of Qingdao UniversityQingdaoShandong 266003China Department of Cardiovascular Surgery The First Affiliated Hospital of Zhejiang UniversityHangzhouZhejiang 310009China Department of Cardiology The Second Affiliated Hospital of Nanchang UniversityNanchangJiangxi 330006China Department of Cardiology Fujian Provincial HospitalFuzhouFujian 350013China Department of Cardiology The First Affiliated Hospital of Dalian Medical UniversityDalianLiaoning 116011China Department of Cardiology Chinese People’s Liberation Army General Hospital(301 Hospital)Beijing 100853China Department of Cardiology The First Affiliated Hospital of Sun Yat-sen UniversityGuangzhouGuangdong 510080China Department of Cardiology Qingdao Municipal HospitalQingdaoShandong 266071China Department of Cardiology Subei People’s HospitalYangzhouJiangsu 225001China Department of Cardiology Yantai Yuhuangding HospitalYantaiShandong 264000China Department of Cardiology Nanfang Hospital of Southern Medical UniversityGuangzhouGuangdong 510515China Department of Cardiovascular Surgery Qilu Hospital of Shandong UniversityJinanShandong 250063China Department of Cardiology Fujian Medical University Union HospitalFuzhouFujian 350001China Department of Cardiology

With accumulating evidence of transcatheter aortic valve replacement(TAVR)worldwide,it is gradually realized that patients being treated are different across different coun-tries,including but not limited to their age,habitus,disease etiology,aortic valve morphology,and sizes of structures.[1]In China,the average age of TAVR patients is around 5 years younger than industrialized countries,[2]making Chinese patients a good predictive sample of what the industrialized countries might see in TAVR screening in the near future due to the expansion of this technique to younger patients,but anatomical features appreciated from multi-slice computed tomography(MSCT)in the Chinese patient population have not been well demonstrated.

关键词： patients aortic younger